SAHPRA Approves Pfizer’s Paxlovid COVID-19 Treatment
SAHPRA announced the registration of Paxlovid COVID-19 treatment, an anti-viral medicine manufactured by Pfizer, to treat COVID-19. This is a 5-day oral treatment for mild to moderate COVID-19 in adults who do not require supplemental oxygen and who are at increased risk for progression to severe COVID-19.
International sources provide guidelines regarding prescribing in liver and kidney disease as well as possible drug interactions including statin therapy, anticoagulation and some hormonal birth control treatments.
Recent Posts
Pioneering MDD Treatment Modeling for Optimal Care Pathways
MDD treatment modeling demonstrates that sequenced interventions for major depressive disorder consistently deliver superior quality-adjusted life years and net monetary benefits compared with no active treatment. All examined pathways outperformed inaction, with an SSRI-first sequence followed b...
Transformative Impact of Levacetylleucine A-T Treatment in Rare Neurodegenerative Disease
Levacetylleucine A-T treatment has delivered compelling Phase III results, producing statistically significant and clinically meaningful improvements in ataxia severity and daily function for both pediatric and adult patients with ataxia-telangiectasia (A-T). The
Insulin Cost Policy Impact on Medicare Beneficiaries
The Insulin Cost Policy Impact became clear in 2023 after the Inflation Reduction Act limited out-of-pocket insulin expenses to $35 per 30-day supply for Medicare Part D beneficiaries. According to a JAMA Network study, the c...